A follow-up end date was defined for each patient as the earliest occurrence of a diabetes endpoint, date of death, date of emigration, date of loss of continuous health or drug plan enrolment, 24 months after start of statin treatment, a dispensing for cerivastatin
, or 31 March 2011.
The lipophilic cerivastatin
has a pyridine-based ring structure.
(25,26,41-43) In fact, the concurrent use of gemfibrozil (Lopid), a fibric acid derivative, was associated with 1/3 of rhabdomyolysis related deaths in patients using cerivastatin
In vitro data suggests that the rank order of cytotoxicity is starts with pravastatin as least toxic, followed by rosuvastatin, pitavastatin, lovastatin, atrovastatin, fluvastatin, simvastatin, and cerivastatin
as the most cytotoxic statin.
(14) Examples of international drug withdrawals have included fulminant liver failure with troglitazone, QT prolongation and ventricular arrhythmias with cisapride, haemolytic anaemia, coagulopathy and renal or hepatic dysfunction with temafloxacin, and fatal rhabdomyolysis with cerivastatin
For example, such popular and widely prescribed drugs as troglitazone, cerivastatin
, rofecoxib, valdecoxib, and cisapride were withdrawn from the market.
As expected, the fat-soluble statin, cerivastatin
, affected the placenta resulting in reduced growth but the researchers also found that pravastatin - the water-soluble statin thought to be potentially compatible for use in pregnancy - had the same detrimental effect.
Sands and his colleagues analyzed pooled data from two previous randomized, controlled trials--ENCORE (Evaluation of Nifedipine and Cerivastatin
on the Recovery of Endothelial Function) and ENACT-1 (Evaluation of Natalizumab as Continuous Therapy)--which included a total intent-to-treat population of 1,414 persons.
Influence of coenzyme QUO) and cerivastatin
on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study.
HMG-CoA reductase inhibitor cerivastatin
prolonged rat cardiac allograft survival by blocking intercellular signals.
Psatsy et al., Potential for the Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin
and Risk of Rhabdomyolysis, 292 J.